The Supreme Cannabis Company, Inc. (TSX: FIRE) is readying itself for Canada's "legalization 2.0" by entering into a definitive agreement with the private company Truverra Inc.
The deal is expected to be valued at around CA$20 million ($15.3 million).
Why It Matters
The acquisition of Truverra gives Supreme further access to the Canadian and international markets through Truverra's Canadian Clinical Cannabinoids Inc. (CCC) subsidiary, the company said in a Wednesday press release.
This includes CCC's 5,000-square-foot Scarborough, Ontario facility, where Supreme said it plans to produce its extracts, including products like concentrates that will be legal for sale later in the year.
In Europe, Supreme will have access to the European CBD market with Truverra Europe's Netherlands-based location.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
In a press release, Supreme CEO Navdeep Dhaliwal discussed the significance of both deals.
"The recent introduction of Health Canada's amended cannabis regulations creates a distinct opportunity for Supreme Cannabis to establish a leading position in the cannabis extracts markets. With the acquisition of Truverra, we secure a Toronto-based facility equipped to extract our high-quality inputs for concentrates and vaping liquids in the near-term."
Truverra's operations provide an additional entry point into the European CBD wellness market, he said.
Supreme Cannabis Acquires Blissco Cannabis In .6M Deal
Supreme Cannabis, Wiz Khalifa's Kush Enterprises Canada Launch Cannabis Oil
Photo courtesy of Supreme Cannabis.
See more from Benzinga
- JJ O'Brien Of PAX Labs Talks Cannabis Partners, Brand Heritage, E-Cig Lessons
- 'No Error To Correct': Why The High Court Turned Down Alpenglow Botanicals' 280E Petition
- California's Assembly Bill 97 Is The State's Latest Attempt To Curtail The Illicit Market
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.